Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.
Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.
The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.
Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.
Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.
Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.
Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.
Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.
Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.
Relapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.
The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.
The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.
REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Cevostamab generated responses and was well tolerated in younger and older patients with relapsed/refractory multiple myeloma.
Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Treatment with standard-of-care isatuximab in patients with relapsed/refractory multiple myeloma is being evaluated in a real-world trial,
Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.
The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.
The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.
Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.
Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.
Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.
Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.
Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.
